Biocon Share Price In Focus As Yesintek Secures Market-Entry Rights In Nine More Global Markets For Stelara Biosimilar

Biocon Limited has secured another step towards expanding the global reach of Yesintek, its proposed biosimilar to Stelara (Ustekinumab). As per a regulatory filing to the stock exchanges, the company has signed a licence agreement with Janssen Sciences Ireland.

The agreement adds nine markets to the product’s commercialisation plans, broadening its potential reach among patients with immune-mediated conditions. Following the announcement, the company’s shares are in focus.

The Biocon share price has fallen 13.7% in the past month and 16.6% so far in 2026.

On the filing date, 26 October 2026, Biocon shares were trading at ₹325.25, up 0.54% at 9:35 am on the National Stock Exchange (NSE). The opening price was ₹323, while the early trade’s high and low stood at ₹325.50 and ₹321.60, respectively.

Biocon Expands Yesintek’s Global Reach

The licensing agreement with Janssen Sciences Ireland clears the way for Yesintek’s commercialisation in:

• Australia

• Brazil

• China

• Hong Kong

• Israel

• Mexico

• New Zealand

• South Korea

• Kazakhstan

The market-entry rights are effective immediately. The company said these arrangements build on earlier agreements covering the United States, Europe, the United Kingdom, Canada and Japan.

The additional rights give Biocon an opportunity to offer what it describes as an affordable and effective treatment option for patients affected by autoimmune diseases in these markets. However, product launches in the countries and regions covered by the agreement remain subject to regulatory approval.

Biocon’s Yesintek Targets Four Immune-Mediated Diseases

Yesintek is a human interleukin-12 and interleukin-23 antagonist. It works by disrupting signalling mediated by these two interleukins in immune-mediated diseases. According to the company statement, the product has been approved for treating Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis.

Stelara recorded worldwide sales of USD 6.08 billion in 2025, according to figures attributed in Biocon’s statement to Johnson & Johnson’s reported sales.

Also Read - Stock Market Update 26 October 2026: Sensex Drops Over 250 Pts; Nifty 50 Below 22,500 At The Opening Bell